Search research articles
Contact Us
Filters
Showing results (291-300 of 321) with videos related to
Page
of 33
Sort By:
Nature Cell Biology
|
June 2, 2014
Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH
Jelena Urosevic, Xabier Garcia-Albéniz, Evarist Planet, et al.
Journal of the National Cancer Institute
|
September 18, 2015
Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis
Milica Pavlovic, Anna Arnal-Estapé, Federico Rojo, et al.
Cell Death & Disease
|
July 18, 2024
The PP2A regulator IER5L supports prostate cancer progression
Jana R Crespo, Natalia Martín-Martín, Saioa Garcia-Longarte, et al.
JNCI Cancer Spectrum
|
August 11, 2021
<i>MAF</i> Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice
Alexander H G Paterson, Peter C Lucas, Stewart J Anderson, et al.
Cell Death & Disease
|
July 22, 2025
Correction: The PP2A regulator IER5L supports prostate cancer progression
Jana R Crespo, Natalia Martín-Martín, Saioa Garcia-Longarte, et al.
Nature Communications
|
September 9, 2022
Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors
Elisa I Rivas, Jenniffer Linares, Melissa Zwick, et al.
Cancer Research
|
September 21, 2018
CANCERTOOL: A Visualization and Representation Interface to Exploit Cancer Datasets
Ana R Cortazar, Veronica Torrano, Natalia Martín-Martín, et al.
Nature Cell Biology
|
November 9, 2023
MAF amplification licenses ERα through epigenetic remodelling to drive breast cancer metastasis
Alicia Llorente, María Teresa Blasco, Irene Espuny, et al.
Medicina Clinica
|
October 19, 2002
[Insulin resistance and its involvement in multiple risk factors associated with type 2 diabetes mellitus]
M Serrano Rios, J F Ascaso Gimilio, E Blázquez Fernández, et al.
Journal of Bone Oncology
|
December 29, 2018
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)
R E Coleman, M Collinson, W Gregory, et al.
Page
of 33
Search research articles
Search
Showing results (291-300 of 321) with videos related to
Sort By:
Page
of 33
Nature Cell Biology
|
June 2, 2014
Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH
Jelena Urosevic, Xabier Garcia-Albéniz, Evarist Planet, et al.
Journal of the National Cancer Institute
|
September 18, 2015
Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis
Milica Pavlovic, Anna Arnal-Estapé, Federico Rojo, et al.
Cell Death & Disease
|
July 18, 2024
The PP2A regulator IER5L supports prostate cancer progression
Jana R Crespo, Natalia Martín-Martín, Saioa Garcia-Longarte, et al.
JNCI Cancer Spectrum
|
August 11, 2021
<i>MAF</i> Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice
Alexander H G Paterson, Peter C Lucas, Stewart J Anderson, et al.
Cell Death & Disease
|
July 22, 2025
Correction: The PP2A regulator IER5L supports prostate cancer progression
Jana R Crespo, Natalia Martín-Martín, Saioa Garcia-Longarte, et al.
Nature Communications
|
September 9, 2022
Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors
Elisa I Rivas, Jenniffer Linares, Melissa Zwick, et al.
Cancer Research
|
September 21, 2018
CANCERTOOL: A Visualization and Representation Interface to Exploit Cancer Datasets
Ana R Cortazar, Veronica Torrano, Natalia Martín-Martín, et al.
Nature Cell Biology
|
November 9, 2023
MAF amplification licenses ERα through epigenetic remodelling to drive breast cancer metastasis
Alicia Llorente, María Teresa Blasco, Irene Espuny, et al.
Medicina Clinica
|
October 19, 2002
[Insulin resistance and its involvement in multiple risk factors associated with type 2 diabetes mellitus]
M Serrano Rios, J F Ascaso Gimilio, E Blázquez Fernández, et al.
Journal of Bone Oncology
|
December 29, 2018
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)
R E Coleman, M Collinson, W Gregory, et al.
Page
of 33